ResearchViral shedding and symptom severity across populations during acute COVID in the ACTIV-2 study
ResearchPitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysis
ResearchHigh usage of telephone telemedicine among people living with HIV at two federally qualified health centers in Los Angeles
ResearchRapid Elimination of Culturable SARS-CoV-2 With Intramuscular or Intravenous Administration of Antiviral Monoclonal Antibody Therapy
ResearchPitavastatin, Procollagen Pathways, and Plaque Stabilization in Patients With HIV: A Secondary Analysis of the REPRIEVE Randomized Clinical Trial
ResearchStatin Effects on the Incidence of Major Non-Cardiovascular Disease Events Among a Global Cohort of People With HIV: A Randomised Controlled Trial
ResearchCardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort
ResearchCoronary Plaque, Inflammation, Subclinical Myocardial Injury, and Major Adverse Cardiovascular Events in the REPRIEVE Substudy
ResearchViral and Symptom Rebound Following Anti-SARS-CoV-2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled Trial
ResearchTixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies
ResearchImplementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial
ResearchPrecision medicine evaluation of heterogeneity of treatment effect for a time-to-event outcome with application in a trial of initial treatment for people living with HIV